Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

Key Points

• Tango Therapeutics is set to release its Q2 2025 earnings report on August 5th, with analysts predicting a loss of ($0.35) per share and revenue of $6.41 million.
• The company's previous earnings report showed a loss of ($0.36) per share, missing expectations, and a revenue of $5.39 million, which was lower than the projected $6.73 million.
• Institutional investors have increased their stakes, with 78.99% of the company's stock now owned by hedge funds and other institutional investors.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Tango Therapeutics to post earnings of ($0.35) per share and revenue of $6.41 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Up 8.1%

Shares of Tango Therapeutics stock traded up $0.49 during mid-day trading on Friday, hitting $6.53. The stock had a trading volume of 5,244,137 shares, compared to its average volume of 1,658,029. The firm has a market cap of $707.81 million, a P/E ratio of -5.35 and a beta of 1.63. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $12.02. The firm has a 50-day moving average of $5.10 and a two-hundred day moving average of $3.05.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC raised its stake in Tango Therapeutics by 270.6% in the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company's stock valued at $483,000 after acquiring an additional 257,668 shares during the period. AQR Capital Management LLC bought a new position in Tango Therapeutics in the 1st quarter worth about $195,000. Woodline Partners LP raised its holdings in shares of Tango Therapeutics by 28.3% in the 1st quarter. Woodline Partners LP now owns 506,188 shares of the company's stock valued at $693,000 after acquiring an additional 111,791 shares in the last quarter. Invesco Ltd. grew its position in Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company's stock worth $97,000 after acquiring an additional 40,983 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its position in shares of Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock worth $35,000 after buying an additional 15,037 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a report on Monday, April 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $10.50.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.